<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html xmlns:n1="urn:hl7-org:v3" xmlns:in="urn:lantana-com:inline-variable-data" xmlns:sdtc="urn:hl7-org:sdtc"><head>
<meta charset="utf-8"><!-- Do NOT edit this HTML directly: it was generated via an XSLT transformation from a CDA Release 2 XML document. --><title>Encounter Summary</title><style type="text/css">
body {
  color: #003366;
  background-color: #FFFFFF;
  font-family: Verdana, Tahoma, sans-serif;
  font-size: 14px;
}

a {
  color: #003366;
  background-color: #FFFFFF;
}

h1 {
  font-size: 20px;
  font-weight: bold;
}

h2 {
  font-size: 18px;
  font-weight: bold;
}

h3 {
  font-size: 14px;
  font-weight: bold;
}

h4 {
  font-size: 14px;
  font-weight: bold;
}


table {
  width: 100%;
}

th {
  background-color: #ffd700;
}

td {
  padding: 0.1cm 0.2cm;
  vertical-align: top;
  background-color: #ffffcc;
}

.h1center {
  font-size: 20px;
  font-weight: bold;
  text-align: center;
  width: 80%;
}

.header_table{
  border: 1pt inset #00008b;
}

.td_label{
  font-weight: bold;
  color: white;
}

.content_span{
 font-family: Verdana, Tahoma, sans-serif;
 display: inline;
 white-space: pre-line;
}

.td_header_role_name{
  width: 20%;
  background-color: #3399ff;
}

.td_header_role_value{
  width: 80%;
  background-color: #ccccff;
}

.Bold{
  font-weight: bold;
}

.Italics{
  font-style: italic;
}

.Underline{
  text-decoration:underline;
}

.internal_format
{
	list-style: none;
	list-style-position:outside;
	margin:0;
	padding:0;
	border:0;
	border-collapse: collapse;
}
          </style></head><body>
<h2><a name="toc">Table of Contents</a></h2><ul><li><a href="#id1">Reason for Referral</a></li><li><a href="#id2">Reason for Visit</a></li><li><a href="#id3">Encounter Details</a></li><li><a href="#id4">Social History</a></li><li><a href="#id5">Last Filed Vital Signs</a></li><li><a href="#id6">Progress Notes</a></li><li><a href="#id7">Miscellaneous Notes</a></li><li><a href="#id8">Plan of Treatment</a></li><li><a href="#id9">Procedures</a></li><li><a href="#id10">Results</a></li><li><a href="#id11">Visit Diagnoses</a></li><li><a href="#id12">Additional Health Concerns</a></li><li><a href="#id13">Care Teams</a></li><li><a href="#id14">Additional Source Comments</a></li></ul><hr align="left" color="teal" size="2"/><h3><a name="id1" href="#toc">Reason for Referral</a></h3><div><ul><li>Nuclear Medicine (Routine) - Authorized: <table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td>Radiology</td><td><p>Diagnoses</p><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p><p>Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (HCC/RAF)</p><br/><p>Procedures</p><p>PETCT with Diagnostic CT of the neck-chest-abd-pelvis w/IV contrast; FDG</p><p>CT SCAN,SOFT TISSUE NECK,W/O CONTRAST</p><p>CT NECK TISSUE CONTRAST</p><p>CT SCAN,THORAX,W/O CONTRAST</p><p>CAT SCAN OF CHEST CONTRAST</p><p>CT SCAN,ABDOMEN,W/O CONTRAST</p><p>CT SCAN OF ABDOMEN CONTRAST</p><p>PET IMAGING CT ATTENUATION SKULL BASE MID-THIGH</p><p>CT SCAN,ABDOMEN AND PELVIS,W/O CONTRAST</p><p>CT SCAN,ABDOMEN AND PELVIS,W CONTRAST</p><p>CT SCAN,SOFT TISSUE NECK,W/O CONTRAST</p><p>CT NECK TISSUE CONTRAST</p><p>CT SCAN,THORAX,W/O CONTRAST</p><p>CAT SCAN OF CHEST CONTRAST</p><p>CT SCAN,ABDOMEN,W/O CONTRAST</p><p>CT SCAN OF ABDOMEN CONTRAST</p><p>PET IMAGING CT ATTENUATION SKULL BASE MID-THIGH</p><p>PET IMAGING CT ATTENUATION SKULL BASE MID-THIGH</p><p>CT SCAN,ABDOMEN AND PELVIS,W/O CONTRAST</p><p>CT SCAN,ABDOMEN AND PELVIS,W CONTRAST</p><p>F18 FDG</p></td><td><p>Master, [REDACTED], DO</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td><td><p>Rad Central Scheduling</p><p>Contact Office for Address</p><p>[REDACTED] 90095</p><p>Phone: [REDACTED]</p></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>50025316125</td><td>Authorized</td><td/><td>[REDACTED]</td><td>[REDACTED]</td><td>1</td><td>1</td></tr></tbody></table><br/><p>Electronically signed by [REDACTED] Master DO at [REDACTED]  5:20 PM PDT</p></li><li>Medication Prior Authorization - Authorized: <table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td/><td><p>Diagnoses</p><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p><br/></td><td><p>Master, [REDACTED], DO</p><p>[REDACTED][REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td><td><p/></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>50025255468</td><td>Authorized</td><td/><td/><td/><td>3</td><td>3</td></tr></tbody></table><br/><p>Electronically signed by [REDACTED] Master DO at [REDACTED] 10:42 AM PDT</p></li></ul></div><h3><a name="id2" href="#toc">Reason for Visit</a></h3><div><ul><li>Consultation and/or Follow-Up (Routine) - Authorized: <table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Specialty</th><th>Diagnoses / Procedures</th><th>Referred By Contact</th><th>Referred To Contact</th></tr></thead><tbody><tr><td>Medicine, Hematology &amp; Oncology</td><td><p>Diagnoses</p><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p><br/><p>Procedures</p><p>OFFICE CONSULTATION,LEVEL V, MDM OR 55+ MINS</p><p>OFFICE/OUTPT VISIT,EST,LEVL III, MDM OR 20+ MINS</p></td><td><p>[REDACTED], MD</p><p>UCLA Health</p><p>[REDACTED][REDACTED][REDACTED]</p><p>[REDACTED][REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td><td><p>Hem Onc Mp2 120</p><p>[REDACTED][REDACTED]</p><p>[REDACTED][REDACTED][REDACTED]</p><p>Phone: [REDACTED]</p><p>Fax: [REDACTED]</p></td></tr></tbody></table><table><colgroup><col width="13%"/><col width="12%"/><col width="25%"/><col width="13%"/><col width="12%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Referral ID</th><th>Status</th><th>Reason</th><th>Start Date</th><th>Expiration Date</th><th>Visits Requested</th><th>Visits Authorized</th></tr></thead><tbody><tr><td>50025190581</td><td>Authorized</td><td/><td>[REDACTED]</td><td>[REDACTED]</td><td>3</td><td>3</td></tr></tbody></table><br/></li></ul></div><h3><a name="id3" href="#toc">Encounter Details</a></h3><div><table><colgroup><col width="10%"/><col width="15%"/><col span="3" width="25%"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter4" class="xRowNormal"><td>[REDACTED] 10:30 AM PDT</td><td ID="encounter4type">Office Visit</td><td><p>UCLA Health- Hematology Oncology Parkside</p><p>[REDACTED][REDACTED]</p><p>Suite 304</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>Master, [REDACTED], DO</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td><content>Primary malignant neoplasm of breast with metastasis (HCC/RAF) (Primary Dx); <br/>Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (HCC/RAF)</content></td></tr></tbody></table></div><h3><a name="id4" href="#toc">Social History</a></h3><div><table ID="sochist10"><colgroup><col span="2" width="25%"/><col width="13%"/><col width="12%"/><col width="25%"/></colgroup><thead><tr><th>Tobacco Use</th><th>Types</th><th>Packs/Day</th><th>Years Used</th><th>Date</th></tr></thead><tbody><tr><td>Smoking Tobacco: Never</td><td/><td ID="sochist10packsperday"/><td/><td/></tr><tr ID="sochist10smokeless" class="xRowAlt"><td>Smokeless Tobacco: Never</td><td/><td/><td/><td/></tr></tbody></table><table><colgroup><col span="2" width="25%"/><col width="50%"/></colgroup><thead><tr><th>Alcohol Use</th><th>Standard Drinks/Week</th><th>Comments</th></tr></thead><tbody><tr><td ID="alcoholStatus">No</td><td>0 (1 standard drink = 0.6 oz pure alcohol)</td><td/></tr></tbody></table><table ID="sdohassess2"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Depression Risk (PHQ)</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess2pair1"><td ID="sdohassess2pair1ques">Total Risk Score based on the patient's PHQ-9 if documented</td><td ID="sdohassess2pair1ans">Not on file</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair2"><td ID="sdohassess2pair2ques">Total Risk Score based on the patient's IP PHQ-2 if documented</td><td ID="sdohassess2pair2ans">Not on file</td><td>[REDACTED]</td></tr><tr ID="sdohassess2pair3"><td ID="sdohassess2pair3ques">Total Risk Score based on the patient's PHQ-2 if documented</td><td ID="sdohassess2pair3ans">Not on file</td><td>[REDACTED]</td></tr></tbody></table><table ID="sdohassess3"><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Social Isolation</th><th>Answer</th><th>Date Recorded</th></tr></thead><tbody><tr ID="sdohassess3pair1"><td ID="sdohassess3pair1ques">How often do you see or talk to people that you care about and feel close to?</td><td ID="sdohassess3pair1ans">Not on file</td><td>[REDACTED]</td></tr></tbody></table><table><colgroup><col width="50%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Sex and Gender Information</th><th>Value</th><th>Date Recorded</th></tr></thead><tbody><tr ID="BirthSex13"><td>Sex Assigned at Birth</td><td ID="BirthSex13Value">Not on file</td><td/></tr><tr ID="GenderIdentity11"><td>Gender Identity</td><td ID="GenderIdentity11Value">Not on file</td><td/></tr><tr ID="SexualOrientation12"><td>Sexual Orientation</td><td ID="SexualOrientation12Value">Not on file</td><td/></tr></tbody></table>documented as of this encounter</div><h3><a name="id5" href="#toc">Last Filed Vital Signs</a></h3><div><table><colgroup><col span="4" width="25%"/></colgroup><thead><tr><th>Vital Sign</th><th>Reading</th><th>Time Taken</th><th>Comments</th></tr></thead><tbody><tr class="xRowNormal"><td class="xcellHeader">Blood Pressure</td><td><span class="content_span">158</span>/<span class="content_span">76</span></td><td>[REDACTED] 11:00 AM PDT</td><td/></tr><tr ID="pulse_5793444000" class="xRowAlt"><td class="xcellHeader">Pulse</td><td>86</td><td>[REDACTED] 11:00 AM PDT</td><td/></tr><tr ID="temp_5793441960" class="xRowNormal"><td class="xcellHeader">Temperature</td><td>36.1 °C (97 °F)</td><td>[REDACTED] 10:26 AM PDT</td><td/></tr><tr ID="resp_5793444000" class="xRowAlt"><td class="xcellHeader">Respiratory Rate</td><td>18</td><td>[REDACTED] 11:00 AM PDT</td><td/></tr><tr ID="SpO2_5793441960" class="xRowNormal"><td class="xcellHeader">Oxygen Saturation</td><td>98%</td><td>[REDACTED] 10:26 AM PDT</td><td/></tr><tr ID="inhaled_" class="xRowAlt"><td class="xcellHeader">Inhaled Oxygen Concentration</td><td>-</td><td>-</td><td/></tr><tr ID="weight_5793441960" class="xRowNormal"><td class="xcellHeader">Weight</td><td>76.2 kg (168 lb)</td><td>[REDACTED] 10:26 AM PDT</td><td/></tr><tr ID="height_5793441960" class="xRowAlt"><td class="xcellHeader">Height</td><td>160 cm (5' 3")</td><td>[REDACTED] 10:26 AM PDT</td><td/></tr><tr ID="bmi_5793441960" class="xRowNormal"><td class="xcellHeader">Body Mass Index</td><td>29.76</td><td>[REDACTED] 10:26 AM PDT</td><td/></tr></tbody></table>documented in this encounter</div><h3><a name="id6" href="#toc">Progress Notes</a></h3><div><ul><li>Master, [REDACTED], DO - [REDACTED] 10:30 AM PDT: <content><content><span class="xLabel">Formatting of this note is different from the original.</span><br/>Outpatient Hematology/Oncology Progress Note<br/><br/>Patient name:  [REDACTED]<br/>MRN:  [REDACTED]<br/>DOB:  [REDACTED]<br/>CSN: 90205827760<br/>Date of encounter: [REDACTED]<br/>Provider: [REDACTED] Master, DO<br/><br/>Reason for appointment: follow up<br/>Underlying disease: breast cancer<br/><br/>HPI: <br/>[REDACTED] is a [REDACTED]. female with PMHx of new CVA in [REDACTED], HTN, dyslipidemia, with a new diagnosis R breast cancer. She is accompanied by her brother [REDACTED]. <br/> <br/>Oncologic history: <br/>Presented with a palpable mass and nipple discharge<br/><br/>[REDACTED] b/l dx mammogram and US: irregular mass measuring 42mm with spiculated margins and associated coarse calcifications measuring 53mm R breast 11:00, oval mass in the R breast lower outer quadrant, irregular mass measuring 22mm with fine pleomorphic calcifications measuring 45mm in the L breast at 12:00, round calcificaitons L breast measuring 32mm, focal asymmetry L breast lower outer quadrant at 4:00 measuring 3mm, round and amorphous calcifications measuring 4mm L breast 8:00<br/><br/>[REDACTED] <br/>R breast CNB 11:00: IDC, grade 2, ER&gt;90%, PR 70%, HER2 1+ FISH negative, Ki67 40-50%<br/>8:00 IDC with lobular features, grade 2, ER&gt;90%, PR 70%, HER2 1+, Ki67 40-50%<br/><br/>[REDACTED] breast MRI: R breast 4-5 enhancing masses ranging from 5-43mm with adjoining areas of NME measuring 75mm, largest mass involves the dermis measuring 33x43x38mm at 11:00, 3 suspicious axillary LNs; L breast irregular mass 17x12x15mm at 11:00, NME 40x26x28mm anteromedial; partially imaged 34mm L hepatic lobe mass<br/><br/>[REDACTED] L breast CNB: IDC, grade 2,  ER &gt;95% 3+, PR 30% 2+, HER2 1+ FISH negative (ratio 1.23, CN 4.73), Ki67 20%<br/><br/>[REDACTED] PET-CT: R breast bx proven carcinoma, R axillary LAD, liver lesion 22x21mm with SUV 8, intense FDG uptake within mixed sclerotic and lytic bone lesions involving spine, ribs, scapula, pelvis, ileum, sacrum, R ischium, scattered pulm micronodules b/l<br/><br/>[REDACTED] started letrozole and verzenio<br/><br/>[REDACTED] PET-CT decreased size R breast mass 30x23mm, decrease size L breast nodule, decrease size R axillary LN and resolved L para-aortic LN, decrease size liver lesion with resolved FDG uptake, significantly decreased FDG uptake in multiple osseous metastases<br/><br/>[REDACTED] decreased verzenio to 100mg <br/><br/>[REDACTED] PET-CT: overall interval stability to further slight decrease in size and near complete resolution of FDG activity of the bilateral breast lesions, lymph nodes, hepatic metastasis. Stable size of numerous predominantly sclerotic osseous metastases with previously FDG-avid bone lesions have significantly decreased in uptake. <br/><br/>[REDACTED] PET-CT: Interval decrease of now mild uptake in the left iliac bone metastases as well as stable size and appearance of bilateral breast lesions and subcentimeter axillary and mediastinal lymph nodes without FDG uptake consistent with response to treatment. <br/> <br/><br/>Subjective: <br/>Here for follow up. <br/>Doing well, no new complaints. <br/><br/>Objective:<br/>Current medications:<br/>Outpatient Medications Prior to Visit <br/>Medication Sig <br/> Abemaciclib (VERZENIO) 100 MG TABS Take 1 tablet (100 mg) by mouth two (2) times daily. <br/> atorvastatin 20 mg tablet Take 1 tablet (20 mg total) by mouth daily. <br/> clopidogrel 75 mg tablet Take 1 tablet (75 mg total) by mouth daily. <br/> DIPHENOXYLATE-ATROPINE 2.5-0.025 mg tablet TAKE ONE TABLET BY MOUTH FOUR TIMES A DAY AS NEEDED FOR DIARRHEA. MAX DAILY AMOUNT: 4 TABLETS <br/> FELODIPINE 5 mg 24 hr tablet TAKE 1 TABLET BY MOUTH DAILY (GENERIC FOR PLENDIL) <br/> hydrALAZINE 25 mg tablet Take 1 tablet (25 mg total) by mouth three (3) times daily. <br/> LETROZOLE 2.5 mg tablet TAKE 1 TABLET BY MOUTH DAILY <br/> METOPROLOL SUCCINATE 50 mg 24 hr tablet TAKE ONE TABLET BY MOUTH DAILY <br/> valsartan 80 mg tablet Take 1 tablet (80 mg total) by mouth daily in addition to 160 mg for total 240 mg daily. <br/><br/>No facility-administered medications prior to visit. <br/><br/>PMHx: <br/>Past Medical History: <br/>Diagnosis Date <br/> Basilar artery narrowing  <br/> Cataract  <br/> Cerebrovascular accident (HCC/RAF) 01/2006 <br/> visual changes and weekness <br/> Hypercholesterolemia  <br/> Hypertension  <br/> Ruptured disk 1986 <br/> Sleep apnea  <br/> Stroke (HCC/RAF) 2006 <br/><br/>Vitals:<br/>BP 160/73  | Pulse 58  | Temp 36.1 °C (97 °F) (Forehead)  | Resp 18  | Ht 160 cm (5' 3")  | Wt 76.2 kg (168 lb)  | SpO2 98%  | BMI 29.76 kg/m² <br/>Reviewed and documented in clinic chart.<br/><br/>General: Appears well-developed, well-nourished and close to stated age. <br/>Head: Normocephalic, atraumatic.<br/>ENT: masked, hearing intact<br/>CV: Regular in rate and rhythm, no murmurs or gallops. <br/>Chest: Clear to auscultation bilaterally without wheezing or rhonchi. <br/>Abdomen: Soft, nontender and nondistended. <br/>Extremities: No edema. <br/>R breast: stable R breast mass 3cm<br/><br/>Recent Labs:<br/><br/>Lab Results <br/>Component Value Date <br/> WBC 3.83 (L) [REDACTED] <br/> HGB 11.2 [REDACTED] <br/> HCT 34.6 [REDACTED] <br/> MCV 104.8 (H) [REDACTED] <br/> NEUTABS 2.27 [REDACTED] <br/><br/>Lab Results <br/>Component Value Date <br/> NA 142 [REDACTED] <br/> K 4.6 [REDACTED] <br/> CL 107 (H) [REDACTED] <br/> CO2 26 [REDACTED] <br/> CREAT 1.09 [REDACTED] <br/> BUN 21 [REDACTED] <br/><br/>Lab Results <br/>Component Value Date <br/> ALT 21 [REDACTED] <br/> AST 29 [REDACTED] <br/> ALKPHOS 57 [REDACTED] <br/> BILITOT 0.3 [REDACTED] <br/><br/>Pertinent imaging:<br/>None interval<br/><br/>Pertinent pathology:<br/>None interval<br/><br/>Impression and Recommendations:<br/>[REDACTED] is a [REDACTED]. female with de novo metastatic breast cancer, ER+/PR+/HER2-<br/>Contralateral breast bx c/w metastatic disease<br/><br/>Reviewed PET-CT results with patient and her brother in detail. Explained I suspect that the L breast lesion is metastatic from the R, although we are still pending ER results which would confirm this is the same biology as the R breast. In addition she has diffuse osseous metastases and a liver lesion. <br/><br/>She is asymptomatic despite diffuse osseous mets<br/><br/>We discussed that while metastatic disease is not curable, it is treatable, and women may still live for years with contemporary therapies. <br/>First line therapy for HR+ disease is with a combination of AI+CDK4/6i. I would also recommend a bone resorptive agent.<br/><br/>Continue verzenio 100mg BID - dose reduced for diarrhea<br/>PET 10/23 demonstrated PR - repeat [REDACTED]<br/>Pending dental evaluation for zometa. Will f/u with dentist after cataract surgery<br/>Thyroid biopsy showing atypia - f/u with surgery and IR for consideration of tx<br/><br/>30 minutes were spent personally by me [REDACTED] on this encounter which include [REDACTED] pre-visit review of the chart, obtaining appropriate history, performing an evaluation, documentation and discussion of management with details supported within the note for [REDACTED] visit. The time documented was exclusive of any time spent on the separately billed procedure.<br/><br/>Return to clinic:<br/>8 weeks - after PET<br/><br/>[REDACTED] Master, DO<br/>UCLA Hematology/Oncology<br/>[REDACTED]<br/>10:46 AM<br/></content><br/><span class="xLabel">Electronically signed by Master, [REDACTED], DO at [REDACTED]  5:21 PM PDT</span><br/></content></li></ul>documented in this encounter</div><h3><a name="id7" href="#toc">Miscellaneous Notes</a></h3><div><ul><li>Interdisciplinary Note - [REDACTED], MA - [REDACTED] 10:30 AM PDT: <content><content><span class="xLabel">Formatting of this note might be different from the original.</span><br/>Patient presented to clinic for blood draw. Labs drawn via venipuncture from patients right arm. </content><br/><span class="xLabel">Electronically signed by [REDACTED], MA at [REDACTED]  5:21 PM PDT</span><br/></content></li></ul>documented in this encounter</div><h3><a name="id8" href="#toc">Plan of Treatment</a></h3><div><table><span style="font-weight:bold; ">Upcoming Encounters</span><colgroup><col width="10%"/><col width="15%"/><col span="3" width="25%"/></colgroup><thead><tr><th>Date</th><th>Type</th><th>Department</th><th>Care Team (Latest Contact Info)</th><th>Description</th></tr></thead><tbody><tr ID="encounter36" class="xRowNormal"><td>[REDACTED]  8:15 AM PST</td><td ID="encounter36type">Ancillary Procedure</td><td><p>[REDACTED] - Radiology</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>Saver, [REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED] 90095-6975</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter35" class="xRowAlt"><td>[REDACTED]  9:00 AM PST</td><td ID="encounter35type">Ancillary Procedure</td><td><p>[REDACTED] - Radiology</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>Saver, [REDACTED], MD</p><p>[REDACTED]</p><p>[REDACTED]-6975</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter34" class="xRowNormal"><td>[REDACTED] 11:30 AM PDT</td><td ID="encounter34type">Telephone</td><td><p>Westwood Neurology</p><p>[REDACTED]</p><p>Suite B200</p><p>[REDACTED], [REDACTED] 90095-0001</p><p>[REDACTED]</p></td><td/><td/></tr><tr ID="encounter33" class="xRowAlt"><td>[REDACTED] 10:15 AM PDT</td><td ID="encounter33type">Office Visit</td><td><p>UCLA Health- Hematology Oncology Parkside</p><p>[REDACTED][REDACTED]</p><p>Suite 304</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>Master, [REDACTED], DO</p><p>[REDACTED][REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr><tr ID="encounter32" class="xRowNormal"><td>[REDACTED] 10:00 AM PDT</td><td ID="encounter32type">Office Visit</td><td><p>[REDACTED][REDACTED]</p><p>[REDACTED][REDACTED]</p><p>2nd Floor [REDACTED]</p><p>[REDACTED]</p><p>[REDACTED]</p></td><td><p>[REDACTED] [REDACTED], OD</p><p>[REDACTED][REDACTED]</p><p>ELW 2nd Floor</p><p>[REDACTED] 90095</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td/></tr></tbody></table>documented as of this encounter</div><h3><a name="id9" href="#toc">Procedures</a></h3><div><table><colgroup><col width="25%"/><col width="10%"/><col width="15%"/><col span="2" width="25%"/></colgroup><thead><tr><th>Procedure Name</th><th>Priority</th><th>Date/Time</th><th>Associated Diagnosis</th><th>Comments</th></tr></thead><tbody><tr ID="procedure44" class="xRowNormal"><td><span class="content_span">CA27.29</span></td><td>Routine</td><td>[REDACTED] 10:52 AM PDT</td><td><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p></td><td><p>Results for this procedure are in the <span class="xLink2-Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540">results section</span>.</p></td></tr><tr ID="procedure42" class="xRowAlt"><td><span class="content_span">CARCINOEMBRYONIC ANTIGEN</span></td><td>Routine</td><td>[REDACTED] 10:52 AM PDT</td><td><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p></td><td><p>Results for this procedure are in the <span class="xLink2-Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541">results section</span>.</p></td></tr><tr ID="procedure41" class="xRowNormal"><td><span class="content_span">COMPREHENSIVE METABOLIC PANEL</span></td><td>Routine</td><td>[REDACTED] 10:52 AM PDT</td><td><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p></td><td><p>Results for this procedure are in the <span class="xLink2-Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345">results section</span>.</p></td></tr><tr ID="procedure43" class="xRowAlt"><td><span class="content_span">CBC &amp; AUTO DIFFERENTIAL</span></td><td>Routine</td><td>[REDACTED] 10:51 AM PDT</td><td><p>Primary malignant neoplasm of breast with metastasis (HCC/RAF)</p></td><td><p>Results for this procedure are in the <span class="xLink2-Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539">results section</span>.</p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id10" href="#toc">Results</a></h3><div><ul><li>PET CT BODY WITH DIAGNOSTIC CT OF THE NECK CHEST ABD PELVIS W/IV CONTRAST ([REDACTED]  2:16 PM PDT): <table><colgroup><col span="2" width="25%"/><col width="50%"/></colgroup><thead><tr><th>Anatomical Region</th><th>Laterality</th><th>Modality</th></tr></thead><tbody><tr><td>Body</td><td/><td>Positron Emission Tomography (PET)</td></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.724400890.Specimen"/><td/><td/><td/><td/></tr></tbody></table><table><thead><tr><th>Impressions</th></tr></thead><tbody><tr><td class="xpre"><p>[REDACTED] 11:23 AM PDT</p><p><span class="content_span"> </span><br/><span class="content_span">History of bilateral breast cancers currently treated with overall stable </span><br/><span class="content_span">findings when compared to PET/CT dated [REDACTED]. No new lesion </span><br/><span class="content_span">identified.</span><br/><span class="content_span"> </span><br/><span class="content_span">   </span><br/><span class="content_span">Thank you for allowing UCLA Oncology Imaging to assist in the care of this </span><br/><span class="content_span">patient.</span><br/><span class="content_span"> </span><br/><span class="content_span">This study has been reviewed jointly by Radiologist [REDACTED], </span><br/><span class="content_span">M.D.  and Nuclear Radiologist [REDACTED], M.D. The above constitutes a </span><br/><span class="content_span">synthesis of both the CT and PET findings and the physicians have reviewed </span><br/><span class="content_span">and are in agreement with the report.</span><br/><span class="content_span"> </span></p></td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p>[REDACTED] 11:23 AM PDT</p><p>This result has an attachment that is not available.</p><p><span class="content_span">UCLA ONCOLOGY IMAGING</span><br/><span class="content_span"> </span><br/><span class="content_span">PET CT BODY WITH DIAGNOSTIC CT OF THE NECK CHEST ABD PELVIS W/IV CONTRAST </span><br/><span class="content_span">[REDACTED]</span><br/><span class="content_span"> </span><br/><span class="content_span">PURPOSE OF PET/CT: Subsequent treatment strategy.</span><br/><span class="content_span"> </span><br/><span class="content_span">ORDER INFORMATION PER REFERRING PROVIDER: metastatic breast cancer, </span><br/><span class="content_span">restaging.</span><br/><span class="content_span"> </span><br/><span class="content_span">CLINICAL HISTORY PER EMR:    .</span><br/><span class="content_span"> </span><br/><span class="content_span">COMPARISON: PET/CT dated [REDACTED].</span><br/><span class="content_span"> </span><br/><span class="content_span">TECHNIQUE: Imaging was performed on a Siemens Multidetector PET CT </span><br/><span class="content_span">Scanner. A single volume noncontrast CT of the upper abdomen was acquired </span><br/><span class="content_span">in quiet breathing. After the administration of intravenous contrast, </span><br/><span class="content_span">volumetric CT scan of the chest was obtained in full suspended </span><br/><span class="content_span">inspiration, and reconstructed at 1 mm and 3 mm. Thereafter, volumetric CT </span><br/><span class="content_span">was acquired from the base of the skull to the proximal-thighs during </span><br/><span class="content_span">shallow breathing at 3 mm. After a standard uptake period following </span><br/><span class="content_span">radiotracer injection, PET images were acquired, using multiple positions </span><br/><span class="content_span">along the same length of the patient's body as the CT. Iterative methods </span><br/><span class="content_span">were used to reconstruct the PET images with a slice thickness of 5 mm. </span><br/><span class="content_span">The CT images were used for attenuation correction. Oral contrast was </span><br/><span class="content_span">administered prior to the examination.</span><br/><span class="content_span"> </span><br/><span class="content_span">Contrast and Radiopharmaceutical: 18-F FDG inj 9.6 millicurie barium </span><br/><span class="content_span">sulfate (Readi-Cat 2) 2.1% susp 450 mL iohexol (Omnipaque) 350 mg/mL inj </span><br/><span class="content_span">100 mL</span><br/><span class="content_span">FDG uptake interval: 66  minutes</span><br/><span class="content_span">Serum glucose: 104 mg/dL</span><br/><span class="content_span"> </span><br/><span class="content_span">RADIATION DOSE: The patient received the following exposure event(s) </span><br/><span class="content_span">during this study, and the dose reference values for each are as shown </span><br/><span class="content_span">(CTDIvol in mGy, DLP in mGy-cm). Note that the values are not patient dose </span><br/><span class="content_span">but numbers generated from scan acquisition factors based on 32 cm (L) </span><br/><span class="content_span">and/or 16 cm (S) phantoms and may substantially under-estimate or </span><br/><span class="content_span">over-estimate actual patient dose based on patient size and other factors. </span><br/><span class="content_span">CT Abd wo, CTDI(L): 10, DLP: 247.3;CT WB, CTDI(L): 14, DLP: 1121.1;CT </span><br/><span class="content_span">LungAbd w, CTDI(L): 13.9, DLP: 592    </span><br/><span class="content_span"> </span><br/><span class="content_span">ONCOLOGIC FINDINGS:</span><br/><span class="content_span"> </span><br/><span class="content_span">History of bilateral breast cancers currently treated with : </span><br/><span class="content_span"> </span><br/><span class="content_span">- Interval further decrease of now mild uptake in the left iliac bone with </span><br/><span class="content_span">SUV max of 1.4 (5-284), previously [REDACTED] = SUV max 1.9 (4-289)</span><br/><span class="content_span">- Stable mild height loss of the T8 vertebral body demonstrates unchanged </span><br/><span class="content_span">diffuse heterogeneous sclerosis. </span><br/><span class="content_span">- Other scattered sclerotic osseous lesions are unchanged and without </span><br/><span class="content_span">abnormal FDG uptake.</span><br/><span class="content_span"> </span><br/><span class="content_span">- Stable appearance without FDG uptake of a nodule along a microclip in </span><br/><span class="content_span">the left breast (5-145).</span><br/><span class="content_span"> </span><br/><span class="content_span">- Stable appearance of subcentimeter right axillary lymph nodes (9-94) </span><br/><span class="content_span"> </span><br/><span class="content_span">-Overall stable size and FDG avidity of the right breast mass measuring 32 </span><br/><span class="content_span">x 19 mm (5-149) SUVmax of 1.2, previously [REDACTED] =  30 x 19 mm (4-152) </span><br/><span class="content_span">SUV max of 1.3</span><br/><span class="content_span"> Persistent mild overlying dermal thickening without significant FDG </span><br/><span class="content_span">uptake. </span><br/><span class="content_span"> </span><br/><span class="content_span">-Stable size hypodense lesion in the segment 7 liver lesion measuring 14 x </span><br/><span class="content_span">8 mm (5-186) with no focal FDG uptake, previously [REDACTED] = 15 x 12 mm </span><br/><span class="content_span">(4-191) </span><br/><span class="content_span"> </span><br/><span class="content_span">-Unchanged focal FDG uptake in a central thyroid nodule with SUVmax 3.5 </span><br/><span class="content_span">(5-91), previously SUV max 3.5</span><br/><span class="content_span"> </span><br/><span class="content_span">ADDITIONAL FINDINGS:</span><br/><span class="content_span"> </span><br/><span class="content_span">PET:</span><br/><span class="content_span">Physiologic FDG uptake is noted in the visualized portions of the brain, </span><br/><span class="content_span">salivary gland tissues, myocardium, the abdominal solid organs, </span><br/><span class="content_span">gastrointestinal tract, both kidneys, ureters and the urinary bladder.</span><br/><span class="content_span"> </span><br/><span class="content_span">For SUV reference:</span><br/><span class="content_span">SUVmean/max liver: 2.1/2.3</span><br/><span class="content_span">SUVmean/max mediastinal blood pool (measured at the descending thoracic </span><br/><span class="content_span">aorta): 2.1/2.4</span><br/><span class="content_span"> </span><br/><span class="content_span">BASE OF HEAD AND NECK:</span><br/><span class="content_span">As above.</span><br/><span class="content_span"> </span><br/><span class="content_span">CHEST:</span><br/><span class="content_span">Lungs: As above. Stable few scattered pulmonary micronodules. Mild </span><br/><span class="content_span">peribronchial thickening with few scattered areas of mucus impaction. </span><br/><span class="content_span">Linear bands within the left lower lobe likely atelectasis/scar.</span><br/><span class="content_span">Lymph nodes and Mediastinum: As above.</span><br/><span class="content_span">Pleura: No pleural effusion.</span><br/><span class="content_span">Cardiovascular: Extensive multivessel coronary calcification of the </span><br/><span class="content_span">coronary arteries. Aortic root calcification. </span><br/><span class="content_span"> </span><br/><span class="content_span">ABDOMEN/PELVIS:</span><br/><span class="content_span">Liver: As above. Hypodense right hepatic lesion without associated FDG </span><br/><span class="content_span">uptake that is incompletely characterized but unchanged (5-179) </span><br/><span class="content_span">Gallbladder and bile ducts: Unremarkable.</span><br/><span class="content_span">Spleen, pancreas, adrenals: Stable low-attenuation lesion in the uncinate </span><br/><span class="content_span">process of the pancreas measuring 12 mm likely sidebranch IPMN</span><br/><span class="content_span">Kidneys and ureters: Normal kidney size. No hydronephrosis. Right kidney </span><br/><span class="content_span">simple appearing renal cysts and unchanged subcentimeter low density </span><br/><span class="content_span">lesion in the left kidney, too small to characterize</span><br/><span class="content_span">Bowel: Small hiatal hernia.</span><br/><span class="content_span">Bladder and reproductive organs: Underdistended urinary bladder.</span><br/><span class="content_span">Lymph nodes: Unremarkable.</span><br/><span class="content_span">Peritoneum: Unremarkable.</span><br/><span class="content_span">Vessels: Hepatic artery arises from the aorta, an anatomic variant.</span><br/><span class="content_span">Abdominal wall: Unremarkable. </span><br/><span class="content_span"> </span><br/><span class="content_span">MUSCULOSKELETAL: </span><br/><span class="content_span">As above.    Demineralized bones with multilevel degenerative changes of </span><br/><span class="content_span">the spine. </span><br/><span class="content_span"> </span></p></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] Master DO</td><td>IMG PET CT ORDERABLES</td></tr></tbody></table></li><li>(ABNORMAL) Comprehensive Metabolic Panel ([REDACTED] 10:52 AM PDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col span="2" width="10%"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp1Name">Sodium</td><td>143</td><td>135 - 146 mmol/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>UCLA OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp1Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp2" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp2Name">Potassium</td><td>4.4</td><td>3.6 - 5.3 mmol/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>UCLA OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp2Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp3" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp3Name">Chloride</td><td><span class="xflagData">108</span><span class="xflagData"> (H)</span></td><td>96 - 106 mmol/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp3Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp4" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp4Name">Total CO2</td><td>24</td><td>20 - 30 mmol/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp4Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp5" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp5Name">Anion Gap</td><td><span class="content_span">11</span></td><td>8 - 19 mmol/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp5Signature"/></tr><tr class="xRowNormal xmergeUp"><td colspan="7"><content class="xallIndent"><span class="xcellHeader">Comment: </span><br/><content class="xpre">Anion gap (AG) is calculated using AG = Na -(Cl+CO2). Variations in the measurements of sodium, chloride, and CO2 can affect AG results. <br/>In patients with hypoalbuminemia, the AG can be "corrected" by adding 2.5 to the calculated anion gap for every 1 g/dL decrease in albumin concentration.<br/></content></content></td></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp6" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp6Name">Glucose</td><td>96</td><td>65 - 99 mg/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>UCLA OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp6Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp7" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp7Name">Creatinine</td><td>1.10</td><td>0.60 - 1.30 mg/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp7Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp8" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp8Name">Estimated GFR</td><td>53</td><td>See GFR Additional Information mL/min/1.73m2</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp8Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp9" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp9Name">GFR Additional Information</td><td><span class="content_span">See Comment</span></td><td/><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp9Signature"/></tr><tr class="xRowNormal xmergeUp"><td colspan="7"><content class="xallIndent"><span class="xcellHeader">Comment: </span><br/><content class="xpre">GFR &gt;89..........Normal <br/>GFR 60 - 89.....Normal to mildly decreased <br/>GFR 45 - 59.....Mildly to moderately decreased <br/>GFR 30 - 44.....Moderately to severely decreased <br/>GFR 15 - 29.....Severely decreased <br/>GFR &lt;15..........Kidney failure <br/>The 2021 CKD-EPI creatinine equation was used to calculate the estimated GFR and assumes stable creatinine concentrations. <br/>Results are in mL/min/1.73 square meters.<br/>The patient's eGFR MAY need to be adjusted for drug dosing. <br/>For drug dosing, utilize eGFR or eCrCl. <br/>If using the eGFR in very large or very small patients, then multiply the reported eGFR by the estimated BSA and divide by 1.73 m2, in order to obtain eGFR in units of mL/min.<br/></content></content></td></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp10" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp10Name">Urea Nitrogen</td><td><span class="xflagData">26</span><span class="xflagData"> (H)</span></td><td>7 - 22 mg/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp10Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp11" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp11Name">Calcium</td><td>9.9</td><td>8.6 - 10.4 mg/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp11Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp12" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp12Name">Total Protein</td><td>7.0</td><td>6.1 - 8.2 g/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp12Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp13" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp13Name">Albumin</td><td>4.0</td><td>3.9 - 5.0 g/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp13Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp14" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp14Name">Bilirubin,Total</td><td>0.4</td><td>0.1 - 1.2 mg/dL</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp14Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp15" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp15Name">Alkaline Phosphatase</td><td>62</td><td>37 - 113 U/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>UCLA OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp15Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp16" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp16Name">Aspartate Aminotransferase</td><td>31</td><td>13 - 62 U/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp16Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp17" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp17Name">[REDACTED]</td><td>22</td><td>8 - 70 U/L</td><td/><td>[REDACTED]  4:14 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Comp17Signature"/></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.Specimen">Blood</td><td/><td>Venipuncture / Unknown</td><td>[REDACTED] 10:52 AM PDT</td><td>[REDACTED]  2:19 PM PDT</td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p/></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] Master DO</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col span="3" width="20%"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.711588345.PerformingLab"><p>UCLA OUTREACH CLINICAL LAB - [REDACTED]</p></td><td><p>[REDACTED][REDACTED]</p></td><td><p>[REDACTED]-6871</p></td><td><p>[REDACTED]</p></td></tr></tbody></table></li><li>CA27.29 ([REDACTED] 10:52 AM PDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col span="2" width="10%"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540.Comp1Name">Cancer Antigen 27.29</td><td><span class="content_span">16.3</span></td><td>&lt;=39.0 U/mL</td><td/><td>[REDACTED]  1:12 AM PDT</td><td>ARUP LABORATORIES</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540.Comp1Signature"/></tr><tr class="xRowNormal xmergeUp"><td colspan="7"><content class="xallIndent"><span class="xcellHeader">Comment: </span><br/><content class="xpre">INTERPRETIVE INFORMATION: Cancer Antigen 27.29<br/> <br/>The CA 27.29 assay is intended for use in monitoring: 1) disease <br/>progression and/or response to therapy in patients with metastatic <br/>disease, and 2) disease recurrence in patients treated previously <br/>for stages II or III breast carcinoma who are clinically free of <br/>the disease. Serial testing in patients who are clinically free of <br/>disease should be used in conjunction with other clinical methods <br/>for early detection of cancer recurrence.<br/> <br/>Limitations: Patients with confirmed breast carcinoma frequently <br/>have CA 27.29 assay values in the same range as healthy <br/>individuals.  Elevations may also be observed in patients with non <br/>malignant disease. Results of this test must always be interpreted <br/>in the context of morphologic and other relevant data, and should <br/>not be used alone for a diagnosis of malignancy.<br/> <br/>Methodology: Siemens Atellica IM BR 27.29 (BR)  chemiluminescent <br/>immunoassay was used. Results obtained with different assay <br/>methods or kits cannot be used interchangeably.<br/>Performed By: ARUP Laboratories<br/>[REDACTED]<br/>[REDACTED]<br/>Laboratory Director: [REDACTED], MD, PhD<br/>CLIA Number: 46D0523979<br/></content></content></td></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540.Specimen">Blood</td><td/><td>Venipuncture / Unknown</td><td>[REDACTED] 10:52 AM PDT</td><td>[REDACTED]  8:51 PM PDT</td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p/></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] Master DO</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col span="3" width="20%"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875540.PerformingLab"><p>ARUP LABORATORIES</p></td><td><p>ASSOC REGIONAL/UNIVERSITY PATH 500 CHIPETA WAY</p></td><td><p>[REDACTED]</p></td><td><p/></td></tr></tbody></table></li><li>CEA ([REDACTED] 10:52 AM PDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col span="2" width="10%"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541.Comp1Name">CEA</td><td><span class="content_span">3.0</span></td><td>&lt;3.1 ng/mL</td><td/><td>[REDACTED]  3:58 PM PDT</td><td>[REDACTED] OUTREACH CLINICAL LAB - [REDACTED]</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541.Comp1Signature"/></tr><tr class="xRowNormal xmergeUp"><td colspan="7"><content class="xallIndent"><span class="xcellHeader">Comment: </span><br/><content class="xpre">Result obtained using an electrochemiluminescence immunoassay on the Roche cobas e801 system.  Values obtained with different method cannot be used interchangeably.<br/>Some smokers may have elevated CEA, usually less than 5.1 ng/mL.<br/> <br/>Ingestion of high levels of biotin in dietary supplements may lead to falsely decreased results.<br/></content></content></td></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541.Specimen">Blood</td><td/><td>Venipuncture / Unknown</td><td>[REDACTED] 10:52 AM PDT</td><td>[REDACTED]  3:01 PM PDT</td></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p/></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] Master DO</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col span="3" width="20%"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875541.PerformingLab"><p>UCLA OUTREACH CLINICAL LAB - [REDACTED]</p></td><td><p>[REDACTED][REDACTED]</p></td><td><p>[REDACTED]-6871</p></td><td><p>[REDACTED]</p></td></tr></tbody></table></li><li>(ABNORMAL) CBC &amp; Auto Differential ([REDACTED] 10:51 AM PDT): <table><colgroup><col width="20%"/><col width="12%"/><col width="8%"/><col width="20%"/><col span="2" width="10%"/><col width="20%"/></colgroup><thead><tr><th>Component</th><th>Value</th><th>Ref Range</th><th>Test Method</th><th>Analysis Time</th><th>Performed At</th><th>Pathologist Signature</th></tr></thead><tbody><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp1" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp1Name">WBC (LabDAQ)</td><td><span class="xflagData">3.42</span><span class="xflagData"> (L)</span></td><td>3.98 - 10.04 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp1Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp2" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp2Name">RBC (LabDAQ)</td><td><span class="xflagData">3.02</span><span class="xflagData"> (L)</span></td><td>3.90 - 6.10 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp2Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp3" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp3Name">Hemoglobin (LabDAQ)</td><td><span class="xflagData">10.3</span><span class="xflagData"> (L)</span></td><td>11.2 - 15.7 g/dL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp3Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp4" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp4Name">Hematocrit (LabDAQ)</td><td><span class="xflagData">32.5</span><span class="xflagData"> (L)</span></td><td>34.1 - 44.9 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp4Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp5" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp5Name">MCV (LabDAQ)</td><td><span class="xflagData">107.6</span><span class="xflagData"> (H)</span></td><td>79.0 - 94.8 fL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp5Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp6" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp6Name">MCH (LabDAQ)</td><td><span class="xflagData">34.1</span><span class="xflagData"> (H)</span></td><td>25.6 - 32.2 pg</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp6Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp7" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp7Name">MCHC (LabDAQ)</td><td><span class="xflagData">31.7</span><span class="xflagData"> (L)</span></td><td>32.2 - 36.5 g/dL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp7Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp8" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp8Name">RDW-CV (LabDAQ)</td><td><span class="xflagData">14.7</span><span class="xflagData"> (H)</span></td><td>11.6 - 14.4 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp8Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp9" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp9Name">Platelets (LabDAQ)</td><td><span class="xflagData">137</span><span class="xflagData"> (L)</span></td><td>163 - 369 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp9Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp10" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp10Name">MPV (LabDAQ)</td><td>10.6</td><td>9.4 - 12.4 fL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp10Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp11" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp11Name">Neutrophil % (LabDAQ)</td><td>57.4</td><td>34.0 - 71.1 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp11Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp12" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp12Name">Lymphocyte % (LabDAQ)</td><td>28.1</td><td>19.3 - 53.1 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp12Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp13" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp13Name">Monocyte % (LabDAQ)</td><td>9.9</td><td>4.7 - 12.5 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp13Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp14" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp14Name">Eosinophil % (LabDAQ)</td><td>2.0</td><td>0.7 - 7.0 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp14Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp15" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp15Name">Basophil % (LabDAQ)</td><td><span class="xflagData">2.3</span><span class="xflagData"> (H)</span></td><td>0.1 - 1.2 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp15Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp16" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp16Name">Neutrophil # (LabDAQ)</td><td>1.96</td><td>1.56 - 6.13 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp16Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp17" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp17Name">Lymphocyte # (LabDAQ)</td><td><span class="xflagData">0.96</span><span class="xflagData"> (L)</span></td><td>1.18 - 3.74 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp17Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp18" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp18Name">Monocyte # (LabDAQ)</td><td>0.34</td><td>0.24 - 0.86 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp18Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp19" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp19Name">Eosinophil # (LabDAQ)</td><td>0.07</td><td>0.04 - 0.54 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp19Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp20" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp20Name">Basophil # (LabDAQ)</td><td>0.08</td><td>0.01 - 0.08 10Â³/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp20Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp21" class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp21Name">IG% (LabDAQ)</td><td>0.3</td><td>0.0 - 5.0 %</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp21Signature"/></tr><tr ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp22" class="xRowAlt"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp22Name">IG# (LabDAQ)</td><td><span class="content_span">0.01</span></td><td>0.00 - 0.50 10E6/uL</td><td/><td>[REDACTED]  4:21 PM PDT</td><td>LABDAQ - PARKSIDE</td><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Comp22Signature"/></tr><tr class="xRowAlt xmergeUp"><td colspan="7"><content class="xallIndent"><span class="xcellHeader">Comment: </span><br/><content class="xpre"> <br/>IG=Immature Granulocytes.<br/> <br/></content></content></td></tr></tbody></table><table><colgroup><col span="5" width="20%"/></colgroup><thead><tr><th>Specimen (Source)</th><th>Anatomical Location / Laterality</th><th>Collection Method / Volume</th><th>Collection Time</th><th>Received Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.Specimen">Blood</td><td/><td/><td>[REDACTED] 10:51 AM PDT</td><td/></tr></tbody></table><table><thead><tr><th>Narrative</th></tr></thead><tbody><tr><td class="xpre"><p/></td></tr></tbody></table><table><colgroup><col width="20%"/><col width="80%"/></colgroup><thead><tr><th>Authorizing Provider</th><th>Result Type</th></tr></thead><tbody><tr><td>[REDACTED] Master DO</td><td>LAB BLOOD ORDERABLES</td></tr></tbody></table><table><colgroup><col span="3" width="20%"/><col width="40%"/></colgroup><thead><tr><th>Performing Organization</th><th>Address</th><th>City/State/ZIP Code</th><th>Phone Number</th></tr></thead><tbody><tr><td ID="Result.1.2.840.114350.1.13.300.2.7.2.798268.714875539.PerformingLab"><p>LABDAQ - PARKSIDE</p></td><td><p>[REDACTED][REDACTED]</p></td><td><p>[REDACTED]-2095, [REDACTED]</p></td><td><p>[REDACTED]</p></td></tr></tbody></table></li></ul>documented in this encounter</div><h3><a name="id11" href="#toc">Visit Diagnoses</a></h3><div><table><colgroup><col width="100%"/></colgroup><thead><tr><th>Diagnosis</th></tr></thead><tbody><tr ID="vdx5" class="xRowNormal"><td><p><span class="content_span">Primary malignant neoplasm of breast with metastasis (HCC/RAF)</span><span class="content_span"> - Primary</span></p></td></tr><tr ID="vdx6" class="xRowAlt"><td><p><span class="content_span">Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (HCC/RAF)</span></p></td></tr><tr ID="vdx47" class="xRowNormal"><td><p><span class="content_span">Primary malignant neoplasm of breast with metastasis (HCC/RAF)</span></p></td></tr><tr ID="vdx48" class="xRowAlt"><td><p><span class="content_span">Malignant neoplasm of central portion of right breast in female, estrogen receptor positive (HCC/RAF)</span></p></td></tr></tbody></table>documented in this encounter</div><h3><a name="id12" href="#toc">Additional Health Concerns</a></h3><div><table><colgroup><col span="2" width="50%"/></colgroup><thead><tr><th>Assessment</th><th>Noted Time</th></tr></thead><tbody><tr class="xRowNormal"><td ID="assessment1">PHQ-9 Depression Total Score: 12</td><td>[REDACTED]  9:49 AM PDT</td></tr><tr class="xRowAlt"><td ID="assessment2">PHQ-2 Depression Total Score: 6</td><td>[REDACTED]  9:49 AM PDT</td></tr></tbody></table>documented as of this encounter</div><h3><a name="id13" href="#toc">Care Teams</a></h3><div><table ID="ct55"><colgroup><col span="3" width="25%"/><col width="13%"/><col width="12%"/></colgroup><thead><tr><th>Team Member</th><th>Relationship</th><th>Specialty</th><th>Start Date</th><th>End Date</th></tr></thead><tbody><tr class="xRowNormal"><td><p>[REDACTED], MD</p><p>NPI: [REDACTED]</p><p>UCLA Health</p><p>[REDACTED][REDACTED][REDACTED]</p><p>[REDACTED]-2139</p><p>[REDACTED] (Work)</p><p>[REDACTED] (Fax)</p></td><td>PCP - General</td><td>Internal Medicine</td><td>[REDACTED]</td><td/></tr></tbody></table>documented as of this encounter</div><h3><a name="id14" href="#toc">Additional Source Comments</a></h3><div>Request medical records from UCLA Health directly by faxing your request to [REDACTED]. Please call [REDACTED] for additional information and assistance.UCLA Health System</div><br/><br/>
</body></html>